First Citizens Financial Corp Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

First Citizens Financial Corp raised its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,647 shares of the biopharmaceutical company’s stock after acquiring an additional 288 shares during the period. First Citizens Financial Corp’s holdings in Pfizer were worth $597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Front Street Capital Management Inc. grew its position in shares of Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares during the last quarter. Lindenwold Advisors grew its position in shares of Pfizer by 1.0% during the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 216 shares during the last quarter. SRS Capital Advisors Inc. grew its position in shares of Pfizer by 1.6% during the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the last quarter. Signet Financial Management LLC grew its position in shares of Pfizer by 0.6% during the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock valued at $1,503,000 after buying an additional 220 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its position in shares of Pfizer by 0.7% during the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after buying an additional 222 shares during the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.

Pfizer Stock Down 0.7 %

PFE stock opened at $40.10 on Friday. Pfizer Inc. has a 12 month low of $39.23 and a 12 month high of $56.32. The firm has a market cap of $225.33 billion, a PE ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64. The firm has a 50 day simple moving average of $43.26 and a 200 day simple moving average of $46.03. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00.

Pfizer (NYSE:PFE – Get Rating) last released its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The business had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. During the same period in the prior year, the business earned $1.08 earnings per share. The business’s quarterly revenue was up 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets lowered their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research note on Wednesday, February 1st. StockNews.com assumed coverage on shares of Pfizer in a research note on Thursday. They set a “buy” rating for the company. SVB Leerink reduced their target price on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a research note on Wednesday, February 1st. Finally, Credit Suisse Group reduced their target price on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.